Kennedy Jr. said Wednesday he would study the abortion pill mifepristone for "safety issues" if confirmed to lead the Department of Health and Human Services. Newsweek reached out to the White House for comment via email.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. STAT is hard at work covering the

Robert F. Kennedy Jr. made several disturbing comments during his first Senate confirmation hearing Wednesday suggesting that, as Donald Trump’s secretary of health and human services, he’s hoping to limit access to the abortion pill mifepristone.

President-elect Trump campaigned on leaving abortion decisions to the states, but that could prove a tough promise to keep as he returns to the Oval Office. Anti-abortion groups want Trump

RFK Jr.'s stance on abortion has put him at odds with the conservative Trump Administration. But his views are changing.

The federal judge who paved a path for abortion drug clearance to reach the Supreme Court has allowed red states to revive the legal battle against mifepristone. | U.S. District Judge Matthew Kacsmaryk ruled Thursday that Idaho,

The Vatican and the U.S. Conference of Catholic Bishops have warned for years that emergency contraceptives could induce abortions in early pregnancies, which pharmaceutical companies have consistently denied.

A new study shows a possible new abortion drug to replace mifepristone. But will these results increase abortion access—or restrict women's reproductive health options down the line?

In the three-hour hearing, Kennedy fielded questions on his interpretation of Title X, late-term abortions, mifepristone, stem-cell research and medical conscience rights.

But anti-abortion advocates have been nevertheless optimistic. In particular, Hawley said she is hopeful that Kennedy and Dr. Marty Makary, Trump’s nominee for Food and Drug Administration ...

Robert F. Kennedy, President Donald Trump's nominee for health and human services secretary, survives two heated confirmation hearings but still faces crucial Senate votes.